Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. Quiver AI Summary MIT and Recursion have released Boltz-2 ...

By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics.

"Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials," said Andrew Kress, CEO of HealthVerity.

On Wednesday, Recursion announced favorable efficacy data in the Phase II trial for REC-994, the company’s lead AI-derived candidate to treat the potentially fatal brain disease, cerebral ...

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI ...

Recursion plucks J&J chief data science officer. Canaan adds ex-Pfizer R&D leader as venture partner. Obesity-focused Metsera unveils leadership team.

"Discover essential data structures for programmers, including arrays, linked lists, stacks, queues, hash tables, trees, graphs, tries, heaps, and binary search trees. Mastering these structures ...